Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabetics with high blood pressure benefit from ’water pills’

28.06.2005


Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT, the largest hypertension clinical trial ever conducted, was led in part by Tulane University physician and epidemiologist Paul K. Whelton, senior vice president for health sciences and lead author for the current report published in the June 27th issue of the Archives of Internal Medicine.

"Almost three out of every four persons with type 2 diabetes has hypertension, putting them at substantial risk for cardiovascular disease," Whelton says.

An important question in patients with type 2 diabetes and hypertension has been whether it makes a difference which medicine is used for initial therapy of high blood pressure.



"ALLHAT is the largest study to address this question, comparing four different classes of antihypertensive medication: diuretics, angiotensin-converting enzyme [ACE] inhibitors, calcium channel blockers and alpha receptor blockers," Whelton says.

In an earlier publication (Journal of the American Medical Association, December 2002), the ALLHAT investigators reported that diuretics were superior in preventing adverse cardiovascular disease outcomes compared with other first-step antihypertensive medications. The current report indicates that this is true not only in hypertensive patients with a normal blood sugar, but in those with diabetes, or an impaired fasting glucose (pre-diabetes).

The Archives publication was based on long-term clinical trial experience in 31,512 men and women who were all 55 years old or older with stage 1 or stage 2 hypertension and at least one additional risk factor for coronary heart disease. Study participants were assigned to initial treatment with either a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril) or a diuretic (chlorthalidone). Compared with the ACE inhibitor and the calcium channel blocker, the diuretic was:

  • More protective against heart failure in patients with or without diabetes (by about 1/6th compared with the ACE inhibitor, and by about 1/3rd compared with the calcium channel blocker).
  • More protective against stroke in people with or without diabetes (compared with the ACE inhibitor). This benefit was seen only in Black patients.
  • Slightly more effective in lowering systolic blood pressure-the measure of blood pressure when the heart beats-among those with or without diabetes.
  • At least equally protective against fatal coronary heart disease or non-fatal heart attacks in diabetics, those with an impaired fasting glucose, and in those with a normal blood sugar.
  • Equally protective against death, end-stage renal disease or cancer in diabetics, those with an impaired fasting glucose, and in those with a normal blood sugar.

"Independent of diabetes status, our results suggest that diuretics are better than ACE inhibitors and calcium channel blockers in preventing certain cardiovascular disease complications-especially heart failure-during initial treatment of high blood pressure. Patients with diabetes and high blood pressure should not change their antihypertensive medications without discussing this option with their doctors," says Whelton.

Madeline Vann | EurekAlert!
Further information:
http://www.tulane.edu

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>